Respiratory Syncytial Virus Matrix Protein Is Sufficient and Necessary to Remodel Host Mitochondria in Infection

Cells. 2023 May 4;12(9):1311. doi: 10.3390/cells12091311.

Abstract

Although respiratory syncytial virus (RSV) is the most common cause of respiratory infection in infants, immunosuppressed adults and the elderly worldwide, there is no licensed RSV vaccine or widely applicable antiviral therapeutics We previously reported a staged redistribution of mitochondria with compromised respiratory activities and increased reactive oxygen species (ROS) generation during RSV infection. Here, we show for the first time that the RSV matrix protein (M) is sufficient and necessary to induce these effects. Ectopically expressed M, but not other RSV proteins, was able to induce mitochondrial perinuclear clustering, inhibition of mitochondrial respiration, loss of mitochondrial membrane potential (Δψm), and enhanced generation of mitochondrial ROS (mtROS) in infection. Truncation and mutagenic analysis revealed that the central nucleic acid-binding domain of M is essential for the effects on host mitochondria, with arginine/lysine residues 170/172 being critically important. Recombinant RSV carrying the arginine/lysine mutations in M was unable to elicit effects on host mitochondria. Further, wild-type but not mutant RSV was found to inhibit the mRNA expression of genes encoding mitochondrial proteins, including Complex I subunits. Importantly, the RSV mutant was impaired in virus production, underlining the importance of M-dependent effects on mitochondria to RSV infection. Together, our results highlight M's unique ability to remodel host cell mitochondria and its critical role in RSV infection, representing a novel, potential target for future anti-RSV strategies.

Keywords: RSV infection; RSV matrix protein (M); host cell mitochondria; respiratory syncytial virus (RSV).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Arginine
  • Humans
  • Lysine
  • Mitochondria / metabolism
  • Reactive Oxygen Species / metabolism
  • Respiratory Syncytial Virus Infections*
  • Respiratory Syncytial Virus, Human*

Substances

  • Reactive Oxygen Species
  • Lysine
  • Arginine

Grants and funding

This research was funded by the National Health and Medical Research Council Australia (Senior Principal Research Fellowship APP1002486/APP1103050 and Project grant APP1043511).